Evvy
Evvy provides at-home vaginal microbiome testing and personalized clinical care to help women and people with vaginas address symptoms, fertility concerns, and menopause-related health issues. The company uses clinical-grade metagenomic sequencing (mNGS) to identify the full range of microorganisms from a single swab, with results reviewed by clinicians and paired with custom treatment plans. Evvy also offers a subscription membership for ongoing microbiome tracking and sells probiotics and prescription symptom-relief products.
- Artificial Intelligence
- Biotechnology
- Consumer Goods
- Digital Health
- Hardware
- Healthcare Technology
- Software Only
- Wellness & Fitness Technology
Funding
Raised to date
$40MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
+5$40M · Series B
Announced Sep 2026 · from article date
Disclosed cumulative: $40M
Founders
Product
Problem
Vaginal health conditions like bacterial vaginosis, yeast infections, and UTIs are extremely common yet frequently misdiagnosed or dismissed, with recurrence rates exceeding 50%. Decades of medical research excluded women, leaving diagnostics and treatment protocols built without female-specific biomarkers, particularly the vaginal microbiome, which remains under-researched and overlooked.
Solution
Evvy provides an at-home vaginal microbiome test and clinical care platform that gives women comprehensive answers about their vaginal health. The test uses clinical-grade metagenomic next-generation sequencing (mNGS) to detect all bacteria, fungi, and other microorganisms from a single swab, providing more reliable and complete results than traditional culture-based methods. Each test result is reviewed by a clinician and comes with a personalized care plan, including prescription treatment when eligible. Evvy's proprietary EvvyAI platform analyzes the world's largest vaginal microbiome dataset to enable novel biomarker discovery and personalized care pathways. An optional membership allows users to track how treatments and behaviors affect their microbiome over time, supporting proactive health management.
Target Audience
Primary customers are women and people with vaginas seeking answers for recurring vaginal symptoms, fertility concerns, or menopause-related health issues, as well as those interested in proactive vaginal health management.
Features
- Clinical-grade mNGS testing that detects the full spectrum of vaginal microorganisms, including bacteria, fungi, and viruses, from a single at-home swab
- EvvyAI platform that translates the company's large-scale vaginal microbiome dataset into personalized care pathways and biomarker discovery
- Clinician-reviewed results with custom action plans, including prescription treatments when eligible, delivered through a telehealth provider group
- Optional subscription membership for longitudinal microbiome tracking to monitor treatment effectiveness and behavioral impacts
- Add-on STI + PCR panel for comprehensive sexual health screening
- Companion products including probiotics, boric acid suppositories, hyaluronic acid suppositories, and vulva creams for symptom relief and microbiome support